CUE News & Events

Cue Biopharma announced that it will receive a $7.5M preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim following Boehringer Ingelheim's selection and approval of its first compound for lead optimization. The company expects to receive the payment in May. Under the terms of the collaboration and license agreement with Boehringer Ingelheim, Cue Biopharma's technology will be leveraged to further research and advance the development of the candidate molecule. The terms of the multi-year collaboration also include the ability of the parties to expand research and development into various B cell targeting bispecifics encompassing autoimmune diseases. Pursuant to the terms of the collaboration, Cue Biopharma is also eligible to earn, in addition, up to approximately $337.5M in additional research, development and commercial milestone-based payments as well as royalty payments on net sales.

Cue Biopharma announced that Lucinda Warren, who has served as Cue Biopharma's chief financial and business officer since February and previously as Cue Biopharma's chief business officer from September 2024 until February, has been appointed interim president and CEO. Usman Azam has stepped down as president and CEO and as a director, effective March 26.

Cue Biopharma announced that it will deliver a poster presentation on the company's lead asset, CUE-401, at the World Immune Regulation Meeting, WIRM, being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases. Title: CUE-401: A Novel Bifunctional TGF-beta/IL-2 Fusion Protein for the Treatment of Autoimmune and Inflammatory Diseases. In CD4+ T effector memory cells, CUE-401 showed TGF-beta-dependent suppression of proinflammatory cytokines, including Th1, Th2, and Th17 responses. In addition, the TGF-beta in CUE-401 prevented activated B cells from differentiating into plasma cells and limited antibody production. In natural killer cells, TGF-beta in CUE-401 counterbalanced the activating effects of interleukin-2, preventing proliferation and upregulation of proinflammatory cytokine production. Together, we believe these results demonstrate that CUE-401 has the potential to provide both short-term control of diverse inflammatory processes via TGF-beta, while also potentially providing durable long-term benefit through the induction and expansion of regulatory T cell responses